Academic performance in Jamaican children with sickle cell disease.

OBJECTIVE: Children with sickle cell disease (SCD) are at risk for neurocognitive deficits that can affect school performance, and psychosocial functioning. The aim of this study was to assess the academic performance of school-aged children with SCD in Jamaica compared to their school peers. METHOD: A cross-sectional survey of academic performance was done in a group of children 11 to 13 years of age, using a standardized state administered examination, the Grade Six Achievement Test (GSAT), covering 5 subjects. Scores were obtained from the Ministry of Education (MOE) for eligible children with SCD, as well as mean scores with standard deviation for unaffected classmates by gender. Socio-demographic and clinical data were obtained from our sickle cell clinic database and an interview administered questionnaire. RESULTS: Sixty-four children satisfied eligibility criteria. Children with SCD had lower percentage scores and significantly lower mean z-scores for 4 of 5 subjects (p < 0.05). Males had significantly lower mean z-scores compared with females. Thirty-seven children (57.8%) were classified as underperformers. Haemoglobin level was a significant predictor of subject score rank. CONCLUSION: Children with SCD in Jamaica perform worse in standardized school examinations than their class peers with boys being particularly vulnerable.

Epilepsy awareness in a Jamaican community: driven to change!

There are relatively few published studies on epilepsy-related knowledge, attitudes, and practices (KAP) from developing countries and none from Jamaica. A questionnaire-based, cross-sectional study of 320 individuals was performed in a small community in Kingston. Residents and employees were comparable in age, sex, and personal and family history of epilepsy, but differed in attained education and occupation. Persons with postsecondary education were less likely to believe that epilepsy is a mental disorder (9% vs 24.8%, P<0.001), is due to demonic possession (8% vs 18.2%, P<0.01), or is contagious (2.5% vs 23%, P<0.001). Overall, 73% felt that people with epilepsy should not drive. The results of this Jamaican KAP study differ from those in other developing countries. There appears to be less societal stigma in Jamaica; however, there is widespread reluctance to allow PWE to drive. This represents a substantial challenge to the current initiative to change existing driving regulations that currently bar people with epilepsy from driving.

Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke.

Chronic transfusion therapy is the treatment of choice for preventing stroke recurrence in children with sickle cell disease (SCD). The majority of children affected by this devastating complication live in the developing world where access to regular blood transfusions may be impractical. Since 2000, in the absence of regular blood supplies, all children at the Sickle Cell Unit who had experienced a first clinical stroke were offered hydroxyurea (HU) as the only intervention to prevent stroke recurrence. Forty-four children were identified as having experienced a first clinical stroke between January 1, 2000 and September 30, 2009; one died at that presentation. Forty-three children were therefore followed for 111 person-years, of whom 10 (23.3%) agreed to start HU. Only one child in the HU group, incidence rate 2/100 person-years, had clinical stroke recurrence, compared to 20/33 in the non-HU group, incidence rate 29/100 person-years (Hazard ratio (HR) 9.4 [95% Confidence interval (CI): 1.3-70.6]; P = 0.03). When the groups were compared, in the non-HU group, four died (vs. zero), 13 (53% vs. 10%) had moderate-severe physical disability (P = 0.017), and 12 (44% vs. 20%) required special education or were too disabled to attend school. Our data support the role of HU as a useful intervention for prevention of stroke recurrence in SCD when transfusion programs are not available or practical.